

Competitive landscape of NK-1 antagonists



LEERINK SWANN

- Emend (MRK)
 - Marketed since 2003
 - Anticipated to generic in 2015 for the oral form, and in 2019 for the IV form
- Netupitant (Helsinn Group & Eisai)
 - In Phase III
 - Being studied in a fixed-dose combination (FDC) with Aloxi (palonosetron)
 - Data readout in 1Q:13